Villoslada, Pablo
Baeza-Yates, Ricardo
Masdeu, Joseph C.
Article History
First Online: 3 August 2020
Change Date: 12 February 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41551-020-00628-2
Competing interests
: P.V. owns stocks and has received consultancy fees from Accure Therapeutics, Health Engineering, QMENTA, Attune Neurosciences, CLight, NeuroPrex and Spiral Therapeutics. These companies are not associated with this work. J.C.M. has received consultancy fees from Biogen and is on their Speaker Bureau, and has received research support from AbbVie, Biogen, Esai, Eli Lilly and Company, and Novartis. R.B.-Y. declares no competing interests.